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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYHuntington’s disease (HD) is a dominant neurodegenerative disorder caused by the expansion of glutamine residues in the N-terminal
region of the huntingtin (HTT) protein. The disease results in progressive neuronal loss, leading to motor, cognitive, and psychiatric
impairment. Here, we report the establishment of neural progenitor cell (NPC) lines derived from induced pluripotent stem cells (iPSCs)
of transgenic HDmonkeys. Upon differentiation to neurons, HD neural cells develop cellular features of HD, including the formation of
nuclear inclusions and oligomeric mutant HTT (mHTT) aggregates, as well as increased apoptosis. These phenotypes are rescued by
genetic suppression of HTT and pharmacological treatment, demonstrating the ability of our HD cell model to respond to therapeutic
treatment. The development and reversal of HD-associated phenotypes in neural cells from HDmonkeys provides a unique nonhuman
primate (NHP) model for exploring HD pathogenesis and evaluating therapeutics that could be assessed further in HD monkeys.INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder caused by the expansion of
CAG repeats in the coding region of the huntingtin
(HTT) gene IT15 (MacDonald et al., 1993). The mutation
produces an extended stretch of glutamine residues span-
ning the N terminus of the HTT protein. Aggregation of
oligomeric mHTT fragments and the formation of nuclear
inclusions have been identified as hallmarks of the disease
(DiFiglia et al., 1997); however, the role of mHTT aggrega-
tion in neurodegeneration remains unclear (Arrasate
et al., 2004). Advances in cellular reprogramming tech-
niques have led to broad applications for induced pluripo-
tent stem cells (iPSCs) derived from patients as a model to
recapitulate disease conditions because they share identical
genetic defects with patients (Grskovic et al., 2011). Recent
studies on iPSCs derived from HD patients have shown
promise as possible HD models (An et al., 2012; Camnasio
et al., 2012; Cheng et al., 2013; HD iPSCConsortium, 2012;
Zhang et al., 2010). As these studies reveal the potential for
pluripotent HD stem cell models as a tool for drug discov-
ery and therapeutic development, the need arises for a pre-
clinical nonhuman primate (NHP) model of HD that will
be ready to assess the safety and efficacy of new therapeu-
tics (Emborg et al., 2013; Perrier and Peschanski, 2012).
Because safety concerns limit the direct translation of find-
ings from human HD iPSC studies, HD monkey modelsStem Cellprovide a unique platform for long-term in vivo assess-
ments, especially in the case of genetic correction and
cell therapies. Here, we report the derivation of NPCs
from HD monkey iPSCs. The resulting HD-NPCs are
capable of differentiating into neural cells and develop
classic HD cellular phenotypes. Furthermore, both genetic
and pharmacologic treatments could reverse HD pheno-
types in HD neural cells. HD monkeys and their derivative
iPSCs provide an unprecedented opportunity for assessing
personal medicine in higher primates, and HD-NPCs are a
unique cellular platform for studying HD pathogenesis
and evaluating drug efficacy.RESULTS
Monkey NPCs Generate GABA+ Neurons following
In Vitro and In Vivo Neural Differentiation
HD monkey dental pulp stromal cells (DPSCs) and fibro-
blasts were reprogrammed by introducing rhesus genes en-
coding OCT4, SOX2, and KLF4 through retroviral gene
transfer following protocols described in our previous
report (Chan et al., 2010; Snyder et al., 2011). HD-iPSC
lines (HD-3 and HD-14) were generated from two HDmon-
keys. HD-2 was embryonic stem cells (ESCs) derived from
transgenic embryos from an HD monkey (Putkhao et al.,
2013) (Table S1 available online). HD cell lines express
exon 1 of the human HTT and green fluorescent proteinReports j Vol. 3 j 585–593 j October 14, 2014 j ª2014 The Authors 585
(legend on next page)
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Reversal of Phenotypes in HD Monkey Neural Cells(GFP) genes under the control of the human polyubiqui-
tin-C promoter (UBC) (Figure S1). HD-2, HD-3, and HD-
14 lines carried CAG repeat sizes of 29, 72, and 27/65,
respectively. Wild-type (WT) cells lines (WT-2, WT-14,
and WT-28) were generated from nontransgenic wild-
type control monkeys derived from ESCs (WT-2 and WT-
28) or by cellular reprogramming (WT-14) (Table S1).
Stem cell lines expressed pluripotent stem cell markers,
including OCT4, SSEA4, Tra-1-60, and alkaline phospha-
tase (Figure S1). In addition, cytogenetic analysis revealed
a normal diploid karyotype matching gender to that of
the HD monkey donor (Figure S1) (Chan et al., 2010; Put-
khao et al., 2013).
To overcome technical hurdles associatedwith long-term
stem cell culture, we derived stable NPC lines from HD
monkey pluripotent stem cells (Figure 1A). NPCs displayed
ectodermal rosette-like structures and exhibited character-
istic NPC morphology after monolayer culture (Figure 1B).
NPC populations were expandable for over 30 passages and
could be frozen and thawed with high viability and main-
tain neural differentiation competency. NPCs expressed ca-
nonical neural precursor markers, including Nestin, PAX6,
Musashi 1 (MSI1), and SOX2, confirmed by immunocyto-
chemistry and quantitative RT-PCR (qRT-PCR) (Figures 1B
and S2). Homogeneity of NPCs was confirmed by fluores-
cence-activated cell sorting (FACS) analysis (Figure 1C
and Table S2). These results showed the successful estab-
lishment of HD- and WT-NPCs at high homogeneity that
can be used for in vitro derivation of neural cells.
To determine that HD-NPCs were capable of differenti-
ating into neuronal cell types, HD-NPCs were cultured
for 21 days on polyornithine/laminin (P/L)-coated glass
slides with neural differentiationmedium (Figure 1A). Neu-
rons derived from HD-NPCs expressed structural neural
markers, microtubule-associated protein (MAP2, 27%),
and b-III tubulin (18%), as well as neurotransmitter
markers g-aminobutyric acid (GABA, 21%) and tyrosine
hydroxylase (TH, 10%), as demonstrated by immunostain-
ing using specific antibodies (Figures 1B and 1D). b-III
tubulin-positive neurons derived from HD-NPCs also
stained positive for neural receptor subunits, including
NR2A, GluR1, and mGluR5 (Figure 1B).Figure 1. Derivation of HD-NPCs from iPSCs and In Vitro Neural D
(A) Schematic diagram depicting NPC and neuron derivation from rhe
(B) Bright-field image of HD-14 NPCs at progressing stages of differe
chemistry of HD-14 NPCs stained for Nestin, PAX6, MSI1, and SOX2 (r
b-III tubulin, MAP2, GABA, and TH (red; third row). Neural receptor su
mGlur5 (red) colabeled with b-III tubulin (green) (fourth row). Nucl
(C) FACS analysis of HD-14 NPCs using antibodies for NPC markers. FA
(D) Quantification of neurons derived from in vitro differentiated N
replicates.
See also Figures S1 and S2 and Table S2.
Stem CellWe further assessed neural differentiation potential for
HD-NPCs in vivo. WT-2 and HD-14 NPCs were trans-
planted into the striatum of 10-week-old SCID mice.
Although HD-NPCs carry both mHTT and GFP transgenes,
WT-NPCs were introduced with lentivirus expressing GFP
gene under the control of the UBC promoter for identifica-
tion. At 12.5, 15, and 16 weeks posttransplantation, the
brains of the transplanted mice were sectioned and stained
for neuronal markers. Confocal imaging revealed that GFP-
positive WT-2 and HD-14 grafts were also positive for
neuronal markers DCX (Figures 2A and 2B), GABA (Figures
2C and 2D), and striatal neuron marker DARPP-32 (Figures
2E and 2F). At 12.5 weeks, WT-2 neurons showed positive
staining for neuronal marker NeuN (Figure 2I). NeuN-pos-
itive HD-14 neurons were seen after 16 weeks (Figure 2J),
suggesting that neural differentiation and maturation
may possibly be impacted by mHTT in HD cells.
Immunostaining with mEM48, an antibody reactive to
mHTT with expanded glutamine repeats (Chan et al.,
2010), revealed grafted cells positive for mHTT inclusions
(Figures 2G and 2H). WT and HD-NPCs were also capable
of generating glial cells as indicated by positive GFAP stain-
ing (Figures 2K and 2L). These results show that iPSC-
derived HD-NPCs survived after xenograft in the striatum
andwere capable of differentiating into striatal GABA+ neu-
rons both in vitro and in vivo.
Expression of mHTT and Formation of Intranuclear
Inclusions during Neural Differentiation
The aggregation of mHTT and the formation of intranu-
clear inclusions are classic HD-associated neuronal pheno-
types (DiFiglia et al., 1997) that have been described in
humans as well as animal models (Wang et al., 2008;
Yang et al., 2008). Although HTT expresses in all cell types,
neuronal cell types are most susceptible to the toxicity
caused by mHTT (Johnson and Davidson, 2010). qRT-
PCR analysis of HD-NPCs during neural differentiation re-
vealed elevated expression of total HTT transcripts in HD
neural cells compared to WT neurons (Figure 3A). Western
blot analysis of HD andWTcells at different stages of differ-
entiation revealed increased accumulation of oligomeric
mHTT in HD-3 and HD-14 (Figure 3B). Interestingly, theifferentiation of HD-NPCs
sus macaque iPSCs.
ntiation. Arrows indicate neural rosettes (first row). Immunocyto-
ed; second row). HD-14 in vitro differentiated neurons stained for
bunits are expressed in HD neural cells; NR2A (red), GluR1 (red), and
ear staining is shown using Hoechst (blue).
CS data for all cell lines are listed in Table S2.
PCs. Error bars indicate the SEM. Data represent three biological
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Figure 2. Characterization of Neuron Differentiation in Grafted NPCs
(A and B) Twelve and a half weeks posttransplantation, WT and HD cell grafts were positive for DCX (red).
(C and D) Fifteen weeks posttransplantation, WT and HD cell grafts were positive for GABA (red).
(E and F) Fifteen weeks posttransplantation, WT and HD cell grafts were positive for DARPP32 (red).
(G and H) Sixteen weeks posttransplantation, WT cell grafts were negative for mEM48; HD cell grafts show colocalization of GFP (green) and
mEM48-positive nuclear inclusions (red).
(I and J) Twelve and a half weeks posttransplantation, WT cell grafts express neuronal marker NeuN (red). NeuN-positive HD cell grafts were
observed after 16 weeks grafting (red).
(K and L) WT and HD cell grafts differentiate to glial cells indicated by positive GFAP staining (red).
Arrows indicate marker-positive transplanted neurons. Scale bars, 10 mm.
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Reversal of Phenotypes in HD Monkey Neural Cellsincreased oligomeric aggregates are only seen in HD neural
cells and are undetectable in HD-iPSCs. Immunostaining
using mEM48 revealed the development of HTT aggregates
and intranuclear inclusions in differentiated HD neurons
colabeled with neuronal markers DCX, MAP2, and GABA
(Figure 3C).
In addition to the development of classic HD cellular
phenotypes, we also investigated whether HD-NPCs were
more susceptible to oxidative stress compared to WT-
NPCs, as previously shown in human HD-iPSCs and neu-
rons (An et al., 2012; HD iPSC Consortium, 2012).
Hydrogen peroxide (H2O2) was supplemented into culture
medium to induce oxidative stress. TUNEL assay following
H2O2 incubation demonstrated a significant increase in cell
death in HD-NPCs compared to WT-NPCs (Figures 3D and
3E; p < 0.01). This observation was further supported by
flow cytometric analysis of caspase 3/7 activity, which
revealed a significant increase in apoptotic cells in HD-
NPCs compared to WT-NPCs following exposure to H2O2
(Figure 3F; p < 0.01). Together, these findings show that
HD neural cells mirror key cellular phenotypes associated
with mHTT.
Reversal of HD-Associated Phenotypes by RNAi and
Memantine
Following the characterization of HD phenotypes in neural
cells derived from HD monkeys, we investigated whether
these phenotypes could be rescued by therapeutic treat-
ment. RNAi-mediated reduction of HTT in HD models
has shown promise in a number of studies (Boudreau
et al., 2009; McBride et al., 2011). We postulated that
reducing the expression of HTT in HD-NPCs would confer
a therapeutic benefit. HD-NPCs were infected with a lenti-
virus expressing small hairpin RNA (shRNA) targeting the
HTT transcript. After Zeocin selection to establish stable
transformed NPC lines, qRT-PCR analysis showed that
HTT expression in shRNA-treated NPCs (shHD-3 and
shHD-14) was reduced by approximately 50% (Figure 4A;
p < 0.05). Furthermore, oligomeric HTT aggregation was
reduced in shHD-3 and shHD-14 as revealed by western
blot using mEM48 antibody (Figure 4B; top panel). Slight
reduction of soluble HTT detected by 1C2 antibody was
also observed in cells treated with shRNA-HTT (Figure 4B;
lower panel). We next determined whether the reduction
of HTT could reduce apoptosis in HD-NPCs. shHD-3 and
HD-3 NPCs were challenged with H2O2 to induce oxidative
stress. As demonstrated by caspase 3/7 assay, the percent-
age of apoptotic cells was significantly reduced in shHD-3
NPCs in comparison to HD-3 NPCs (Figure 4C; p < 0.01).
Next, we performed TUNEL assay to assess cell death in
shHD-3 and shHD-14 neural cells following differentia-
tion. In correlation with our caspase assay, we observed a
significant reduction of apoptotic neural cells that hadStem Cellreduced HTT expression compared to HD neural cells not
expressing shRNA (Figure 4D; p < 0.05).
In addition to mHTT expression, neurodegeneration
has been attributed to N-methyl-D-aspartate receptor
(NMDAR)-mediated cytotoxicity in HD (Marco et al.,
2013). Reports of using memantine, a well-characterized
NMDAR antagonist, have shown some promise as a poten-
tial therapy for HD (Milnerwood et al., 2010). To test
whether treatment with memantine could rescue the cell
death observed in HD neurons, 10 mMmemantine was sup-
plemented intoneural differentiationmedium24hrprior to
assessing cytotoxicity. The cytotoxicity of HD neurons
treated with memantine was significantly reduced com-
pared tountreatedHDneurons,whereas therewasno signif-
icant change in cytotoxicity in WT neurons (Figure 4E; p <
0.01). Together, these results show that HD monkey neural
cells respond topotential therapeutic treatments, suggesting
our model will be useful as a platform for drug assessment.DISCUSSION
This study reports the development of an HD-NPC model
derived from the iPSCs of HD NHPs. We established stable
and expandable NPC lines from HD monkeys that are
capable of neural differentiation in vitro and in vivo. HD
neural cells develop classic cellular phenotypes of HD
that could be reversed using both genetic and pharmaco-
logical treatments. Though efforts to differentiate iPSCs
or directly differentiate somatic cells to target cells of inter-
est are ongoing, establishing potent NPC lines from iPSCs
provides an advantage by allowing easy maintenance of a
progenitor cell population committed to the neuronal line-
age, thus enhancing homogeneity in subsequent neural
differentiation (Koch et al., 2009). Such HD-NPC lines are
important for in vitro neural differentiation for drug dis-
covery research, whereas competency in in vivo differenti-
ation is important for cell replacement therapy.
In vitro differentiationmethods used in this systemwere
similar to protocols described for human iPSC neural differ-
entiation, resulting in neurons positive for GABA, TH, and
mature neural markers. NPC grafts after in vivo differentia-
tion were positive for glial marker GFAP andmature neural
markers; however, we noticed that survival of NPCs and de-
rivative neural cells at the graft site was more impaired in
HD-NPCs compared to the contralateral side implanted
withWT-NPCs. A possible explanation for this observation
is that only 50,000 NPCs were grafted into the mouse stria-
tum. This number is relatively low compared to other
studies that grafted over 100,000 cells (Nicholas et al.,
2013; Nori et al., 2011). Furthermore, in this study NPCs
were transplanted as a single cell suspension, potentially
leading to reduced survival of cell grafts compared to otherReports j Vol. 3 j 585–593 j October 14, 2014 j ª2014 The Authors 589
Figure 3. Elevated Expression and Aggregation of mHTT Accompany Increased Vulnerability to Oxidative Stress in HD Cells
(A) qRT-PCR analysis of HTT exon 1 during in vitro neural differentiation. Expression levels are compared to WT-2 neuron control line.
Results were from three biological replicates. qRT-PCR samples run in duplicate. Data and error bars are represented as mean ± SEM.
(B) Western blot analysis revealed an increase in oligomeric mHTT that correlates with neuronal differentiation stage. Notice aggregate
accumulation in the stacking gel (above 250 kDa). Negative () and positive (+) lanes are frontal cortex samples from nontransgenic and
HD monkeys, respectively.
(legend continued on next page)
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Figure 4. Reversal of HD-Associated Phe-
notypes Using shRNA and Memantine
(A) qRT-PCR analysis of HTT exon 1 expres-
sion in HD-3 and HD-14 NPCs after infection
with lentivirus expressing shRNA-HTT. Re-
sults shown from three biological repli-
cates, qRT-PCR samples run in duplicate.
Data and error bars are represented as
mean ± SEM (*p < 0.05, ANOVA).
(B) Western blot analysis of mHTT aggre-
gation in HD-3 and HD-14 NPCs and in vitro
differentiated neural cells with (+) or
without () expressing shRNA-HTT.
(C) Quantification of caspase 3/7-positive
HD-3 and shHD-3 NPCs following H2O2
exposure. Values represent fold change from
untreated sample. Results are shown from
three biological replicates. Data and error
bars are represented as mean ± SEM (**p <
0.001, ANOVA).
(D) Quantification of TUNEL assay on HD-3
and HD-14 neurons after in vitro differen-
tiation with or without expressing shRNA-
HTT. Percentage of TUNEL-positive cells
calculated from total number of cells iden-
tified by Hoechst staining. Results are
shown from three biological replicates. Data
and error bars are represented as mean ±
SEM (*p < 0.05, ANOVA).
(E) Cytotoxicity profile of neurons treated
with 10 mM memantine drug measured by
G6PD assay. Values represent mean fold
change in cytotoxicity from untreated cells.
Cytotoxicity values averaged from two HD
lines (HD-2, HD-3) and two WT lines (WT-2,
WT-28) from three repeated experiments.
Data and error bars are represented as
mean ± SEM (*p < 0.05, ANOVA).
Stem Cell Reports
Reversal of Phenotypes in HD Monkey Neural Cellstransplantation studies that graft neurospheres (Nori et al.,
2011). Together, these results cohere with our findings that
the progressive increase in mHTT expression and the accu-
mulation of oligomericmHTT inneural differentiatingHD-(C) Left: staining of in vitro differentiated HD-NPCs with mEM48 (red
(arrowhead) of mHTT. Middle left: mHTT inclusions (green) colabeled w
MAP2 (right; red). Right: mHTT inclusions and neuropil aggregates (ar
(blue). Arrows indicate intranuclear inclusions.
(D) Images represent TUNEL staining of WT-2 and HD-14 NPCs after 24
is shown using Hoechst (blue).
(E) Quantification of TUNEL assay on HD- and WT-NPCs following H2O2
HD lines (HD-2, HD-3, HD-14) and three WT lines (WT-2, WT-14, WT
number of cells from three biological replicates of each cell line. Dat
(F) Quantification of caspase 3/7-positive HD-NPCs compared to WT-N
averaged for three HD lines (HD-2, HD-3, HD-14) and two WT lines (W
Results are shown from three biological replicates of each cell line. Data
Stem CellNPCs, combinedwith reduced tolerance to oxidative stress,
result in a higher apoptotic rate and increased cell death.
As a potential platform to model HD cellular pathogen-
esis, an important goal of this study was to assess whether) reveals distinct intranuclear inclusions and cytosolic aggregates
ith DCX (red). Middle right: mHTT inclusions (green) colabeled with
rowhead; green) colabeled with GABA (red). Staining using Hoechst
hr H2O2 challenge. H2O2 TUNEL-positive cells (red). Nuclear staining
exposure. TUNEL-positive cell (percentage) was averaged for three
-28). Percentage of TUNEL-positive cells was calculated from total
a are represented as mean ± SEM (**p < 0.001, ANOVA).
PCs following H2O2 exposure. Apoptotic population percentage was
T-2, WT-14). Values represent fold change from untreated sample.
and error bars are represented asmean± SEM (**p < 0.001, ANOVA).
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logic events. We found that an increase of intranuclear in-
clusions and the accumulation of oligomeric, soluble, and
insoluble mHTT aggregates were correlated with neuronal
differentiation. This observation mirrors a key neural
pathology seen in HD patients’ brains, as well as in HD
monkey models (DiFiglia et al., 1997; Yang et al., 2008).
In addition to mHTT aggregation, HD-NPCs show in-
creased apoptosis induced by exposure to H2O2 as a means
of inducing oxidative stress. This disease-dependent differ-
ence in vulnerability to exogenous stress recapitulates phe-
notypes characterized by various studies using human
pluripotent stem cells (HD iPSC Consortium, 2012). These
findings suggest that our in vitro system is comparable to
other previously described cellular models using HD-
NPCs, and derivative neural cells develop pronounced
HD cellular phenotypes. Furthermore, these HD pheno-
types develop independent of treatment with proteasome
inhibitors, which in some reports were necessary to induce
HD-associated phenotypes (Cheng et al., 2013).We suspect
that, unlike human iPSCs, our HD-NPCs express multiple
copies of the truncatedmHTT gene with an expanded pol-
yglutamine tract regulated by the UBC promoter, which
may lead to more dramatic phenotypes and impact neural
differentiation.
The capability of HD monkey neural cells to respond to
in vitro drug and gene therapy provides a proof of principle
that this cellular model of HD could make a powerful
resource for the assessment and development of candidate
therapeutic strategies. By using an RNAi approach to
reduce HTTexpression and by treating neurons with mem-
antine, we were able to ameliorate cell death phenotypes.
With this result, we show the potential utility of our system
for screening therapeutic targets in HD, with the important
bonus that our model provides a unique opportunity for
future assessments in HD monkeys in vivo. Furthermore,
reports describing the successful transplantation and inte-
gration of monkey neural progenitors into targeted brain
regions of NHPs (Emborg et al., 2013; Hashimoto et al.,
2012) point to the feasibility of cell replacement studies
in NHP models of neurodegenerative disease. These re-
ports, combined with our recent success in developing
HD monkeys (Chan et al., 2014; Kocerha et al., 2013;
Yang et al., 2008), lay the foundation for long-term assess-
ment of the safety and efficacy of cell and gene therapies in
HD monkey models.EXPERIMENTAL PROCEDURES
In Vitro/In Vivo Neuronal Differentiation
NHP NPCs were seeded onto a P/L-coated glass chamber in differ-
entiation medium (DMEM/F12 [Life Technologies], P/S [Invitro-
gen], 2 mM L-glutamine, 1 3 N2 [Invitrogen], and 1 3 B27 [Life592 Stem Cell Reports j Vol. 3 j 585–593 j October 14, 2014 j ª2014 The ATechnologies]). At 4 days of neural induction, SHH (R&D Systems,
0.2 mg/ml) and FGF8 (R&D, 0.1 mg/ml) were added. At day 8,
200 mM ascorbic acid was added in combination with SHH
and FGF8.
All protocols involving animal care and handling were approved
by Emory University’s Institutional Animal Care and Use Commit-
tee. For in vivo differentiation to the neuronal lineage,WT-2 NPCs
andHD-14NPCswere dissociated and suspended at 50,000 cells/ml
in artificial cerebrospinal fluid solution. By stereotactic injection,
the cell suspensionwas infused into the right and left hemispheres
of the striatum. Further details are in the Supplemental Experi-
mental Procedures.
Cell Stress and Apoptosis Assays
NPCs were treated with 5 mM H2O2 in culture medium for 24 hr.
Caspase 3/7 activity was assessed using Muse Caspase-3/7 Kit
(Millipore) according to the manufacturer’s instructions. Cell
counts were analyzed usingMuse Cell Analyzer (Millipore). Effects
of H2O2 were further assessed by TUNEL analysis as described in
the Supplemental Experimental Procedures.
Statistical Analysis
For all comparisons one-way ANOVA analysis and Bonferonni
post tests were performed using SPSS statistical software (IBM).
Statistical significance was determined at *p < 0.05 and **p <
0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimen-
tal Procedures, two figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2014.07.011.
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